Rare disease biotech Ultragenyx files for a $86 million IPO


Shutterstock photo

Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for metabolic genetic diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Novato, CA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol RARE. Ultragenyx initially filed confidentially on October 4, 2013. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com